The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10623 malaria professionals are enjoying the free benefits of MalariaWorld today

Afghanistan

An unlabelled probe-based real time PCR and modified semi-nested PCR as molecular tools for analysis of chloroquine resistant Plasmodium vivax isolates from Afghanistan

July 15, 2020 - 15:19 -- Open Access
Author(s): 
Sayed Hussain Mosawi, Abdolhossein Dalimi, Najibullah Safi, Reza Fotouhi-Ardakani, Fatemeh Ghaffarifar and Javid Sadraei
Reference: 
Malaria Journal 2020 19:253, 14 July 2020

Plasmodium vivax resistance to chloroquine (CQ) has been reported from many endemic regions in the world. Plasmodium vivax is responsible for 95% of malaria cases in Afghanistan and CQ is the first-line treatment given for vivax malaria. The pvmdr-1 and pvcrt-o (K10 insertion) genes are possible markers for CQ-resistance in P. vivax isolates. There have been no studies done on the presence or absence of molecular markers for CQ-resistance P. vivax in Afghanistan. The present work aimed to evaluate the frequency of mutations in the pvmdr-1 and K10 insertion in the pvcrt-o genes of P. vivax.

Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017

July 15, 2020 - 15:13 -- Open Access
Author(s): 
Kasama Rakmark, Ghulam R. Awab, Jureeporn Duanguppama, Usa Boonyuen, Arjen M. Dondorp and Mallika Imwong
Reference: 
Malaria Journal 2020 19:251, 14 July 2020

Plasmodium vivax is the predominant Plasmodium species in Afghanistan. National guidelines recommend the combination of chloroquine and primaquine (CQ-PQ) for radical treatment of P. vivax malaria. Artesunate in combination with the antifolates sulfadoxine-pyrimethamine (SP) has been first-line treatment for uncomplicated falciparum malaria until 2016. Although SP has been the recommended treatment for falciparum and not vivax malaria, exposure of the P. vivax parasite population to SP might still have been quite extensive because of community based management of malaria. The change in the P. vivax antifolate resistance markers between 2007 and 2017 were investigated.

NOT Open Access | The comparison of Real-time-PCR-HRM and Microscopy Methods for Detection of Mixed Plasmodium spp. Infections in Laghman Province, Afghanistan

July 6, 2020 - 16:44 -- NOT Open Access
Author(s): 
Dalimi A, Mosawi SH
Reference: 
Infect Disord Drug Targets. 2020 Jul 2

Laghman province, in the east of the Afghanistan, is one of the most malaria endemic regions with an eminence of Plasmodium vivax and Plasmodium falciparum. So far, no study has been conducted to investigate the extent of mixed infections in this area.

Not Open Access | Improving Compliance with Malaria Chemoprophylaxis in Afghanistan

December 19, 2012 - 11:39 -- NOT Open Access
Author(s): 
Brisson, Paul; Woll, Michael; Brisson, Michael
Reference: 
Military Medicine, Volume 177, Number 12, December 2012 , pp. 1539-1542(4)
MalariaWorld

During their deployment to Afghanistan, the authors identified a low compliance rate with malaria chemoprophylaxis. A performance improvement project was developed to improve compliance.

Subscribe to RSS - Afghanistan